Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Neamine. |
| Metocurine iodide | The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Neamine. |
| Gallamine triethiodide | The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Neamine. |
| Cisatracurium | Neamine may increase the neuromuscular blocking activities of Cisatracurium. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be increased when used in combination with Neamine. |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Neamine. |
| Doxacurium | The therapeutic efficacy of Doxacurium can be increased when used in combination with Neamine. |
| Mivacurium | The therapeutic efficacy of Mivacurium can be increased when used in combination with Neamine. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Neamine. |
| Metocurine | The therapeutic efficacy of Metocurine can be increased when used in combination with Neamine. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be increased when used in combination with Neamine. |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be increased when used in combination with Neamine. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be increased when used in combination with Neamine. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Neamine. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Neamine. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Neamine. |
| Atracurium | The therapeutic efficacy of Atracurium can be increased when used in combination with Neamine. |
| Gallamine | The therapeutic efficacy of Gallamine can be increased when used in combination with Neamine. |
| Alcuronium | The therapeutic efficacy of Alcuronium can be increased when used in combination with Neamine. |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be increased when used in combination with Neamine. |
| Carboplatin | The risk or severity of ototoxicity and nephrotoxicity can be increased when Neamine is combined with Carboplatin. |
| Foscarnet | The risk or severity of nephrotoxicity can be increased when Neamine is combined with Foscarnet. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Neamine. |
| Tenofovir disoproxil | Neamine may increase the nephrotoxic activities of Tenofovir disoproxil. |
| Tenofovir alafenamide | Neamine may increase the nephrotoxic activities of Tenofovir alafenamide. |
| Tenofovir | Neamine may increase the nephrotoxic activities of Tenofovir. |
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Neamine. |
| Zoledronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Zoledronic acid. |
| Alendronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Alendronic acid. |
| Ibandronate | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Ibandronate. |
| Clodronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Clodronic acid. |
| Risedronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Risedronic acid. |
| Etidronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Etidronic acid. |
| Incadronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Incadronic acid. |
| Pamidronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Pamidronic acid. |
| Tiludronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Tiludronic acid. |
| Cyclosporine | The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Neamine. |
| Icosapent | The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Neamine. |
| Cefotiam | The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Neamine. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Neamine. |
| Cefmenoxime | The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Neamine. |
| Cefmetazole | The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Neamine. |
| Indomethacin | The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Neamine. |
| Cidofovir | The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Neamine. |
| Triamterene | The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Neamine. |
| Cefpiramide | The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Neamine. |
| Ceftazidime | The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Neamine. |
| Loracarbef | The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Neamine. |
| Framycetin | The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Neamine. |
| Cefalotin | The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Neamine. |
| Nabumetone | The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Neamine. |
| Ketorolac | The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Neamine. |
| Tenoxicam | The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Neamine. |
| Celecoxib | The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Neamine. |
| Cefotaxime | The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Neamine. |
| Tolmetin | The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Neamine. |
| Rofecoxib | The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Neamine. |
| Piroxicam | The risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Neamine. |
| Methotrexate | The risk or severity of nephrotoxicity can be increased when Methotrexate is combined with Neamine. |
| Cephalexin | The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Neamine. |
| Fenoprofen | The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Neamine. |
| Valaciclovir | The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Neamine. |
| Valdecoxib | The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Neamine. |
| Diclofenac | The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Neamine. |
| Sulindac | The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Neamine. |
| Bacitracin | The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Neamine. |
| Amphotericin B | The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Neamine. |
| Cephaloglycin | The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Neamine. |
| Flurbiprofen | The risk or severity of nephrotoxicity can be increased when Flurbiprofen is combined with Neamine. |
| Adefovir dipivoxil | The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Neamine. |
| Pentamidine | The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Neamine. |
| Etodolac | The risk or severity of nephrotoxicity can be increased when Etodolac is combined with Neamine. |
| Mefenamic acid | The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Neamine. |
| Acyclovir | The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Neamine. |
| Naproxen | The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Neamine. |
| Sulfasalazine | The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Neamine. |
| Phenylbutazone | The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Neamine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Neamine is combined with Meloxicam. |
| Carprofen | The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Neamine. |
| Cefaclor | The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Neamine. |
| Diflunisal | The risk or severity of nephrotoxicity can be increased when Diflunisal is combined with Neamine. |
| Tacrolimus | The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Neamine. |
| Ceforanide | The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Neamine. |
| Salicylic acid | The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Neamine. |
| Meclofenamic acid | The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Neamine. |
| Acetylsalicylic acid | The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Neamine. |
| Oxaprozin | The risk or severity of nephrotoxicity can be increased when Oxaprozin is combined with Neamine. |
| Hydrochlorothiazide | The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Neamine. |
| Ketoprofen | The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Neamine. |
| Balsalazide | The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Neamine. |
| Ibuprofen | The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Neamine. |
| Cefditoren | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Neamine. |
| Atazanavir | The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Neamine. |
| Colistimethate | The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Neamine. |
| Cefuroxime | The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Neamine. |
| Cefapirin | The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Neamine. |
| Cefadroxil | The risk or severity of nephrotoxicity can be increased when Cefadroxil is combined with Neamine. |
| Cefprozil | The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Neamine. |
| Ceftriaxone | The risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Neamine. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Neamine is combined with Olsalazine. |